Analysts Set Assembly Biosciences, Inc. (NASDAQ:ASMB) Target Price at $41.00

Shares of Assembly Biosciences, Inc. (NASDAQ:ASMB) have received a consensus rating of “Moderate Buy” from the eight research firms that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating on the company. The average 12-month price target among analysts that have covered the stock in the last year is $41.00.

ASMB has been the topic of several research reports. Mizuho set a $40.00 target price on Assembly Biosciences and gave the company an “outperform” rating in a report on Thursday, November 20th. HC Wainwright reissued a “buy” rating and issued a $50.00 price objective on shares of Assembly Biosciences in a research note on Monday, December 22nd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Assembly Biosciences in a report on Wednesday, January 21st.

Assembly Biosciences Trading Down 2.7%

ASMB stock opened at $25.71 on Tuesday. The company’s 50-day moving average price is $32.80 and its 200 day moving average price is $28.04. Assembly Biosciences has a 52 week low of $7.75 and a 52 week high of $39.71. The company has a market cap of $406.73 million, a P/E ratio of -5.37 and a beta of 1.14.

Assembly Biosciences (NASDAQ:ASMB) last announced its quarterly earnings results on Monday, November 10th. The biopharmaceutical company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.50) by ($0.22). The firm had revenue of $10.79 million for the quarter, compared to analysts’ expectations of $7.46 million. Assembly Biosciences had a negative return on equity of 59.01% and a negative net margin of 103.65%. On average, equities research analysts expect that Assembly Biosciences will post -6.87 earnings per share for the current year.

Hedge Funds Weigh In On Assembly Biosciences

Several hedge funds have recently bought and sold shares of the stock. Palumbo Wealth Management LLC raised its holdings in shares of Assembly Biosciences by 7.2% in the fourth quarter. Palumbo Wealth Management LLC now owns 37,305 shares of the biopharmaceutical company’s stock worth $1,269,000 after acquiring an additional 2,507 shares during the last quarter. Geode Capital Management LLC increased its position in Assembly Biosciences by 6.9% during the 2nd quarter. Geode Capital Management LLC now owns 51,015 shares of the biopharmaceutical company’s stock worth $925,000 after purchasing an additional 3,312 shares in the last quarter. Bank of America Corp DE raised its stake in Assembly Biosciences by 6,382.7% in the 3rd quarter. Bank of America Corp DE now owns 3,371 shares of the biopharmaceutical company’s stock valued at $86,000 after purchasing an additional 3,319 shares during the last quarter. Acadian Asset Management LLC lifted its holdings in Assembly Biosciences by 42.1% in the 1st quarter. Acadian Asset Management LLC now owns 23,027 shares of the biopharmaceutical company’s stock valued at $219,000 after purchasing an additional 6,823 shares in the last quarter. Finally, Qube Research & Technologies Ltd acquired a new stake in shares of Assembly Biosciences during the 3rd quarter worth about $282,000. Hedge funds and other institutional investors own 19.92% of the company’s stock.

About Assembly Biosciences

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.